Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study of Neoadjuvant Tislelizumab (BGB-A317, anti-PD-1 antibody) combined with Cisplatin and Gemcitabine for cT2-T4aN0M0 Bladder Urothelial Cancer

X
Trial Profile

A Multicenter Study of Neoadjuvant Tislelizumab (BGB-A317, anti-PD-1 antibody) combined with Cisplatin and Gemcitabine for cT2-T4aN0M0 Bladder Urothelial Cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Tislelizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2023 Primary endpoint (pathologic complete response (pCR, pT0N0M0)) has been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Final results (n=63; data cut off 14 Dec 2022) assessing the efficacy and safety of tislelizumab in patients with muscle-invasive bladder urothelial cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2022 Status changed from not yet recruiting to recruiting, as per presented at the 58th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top